COSMO IS A PHARMACEUTICAL COMPANY WITH A FOCUS ON GASTROINTESTINAL DISEASES, DERMATOLOGY AND HEALTHTECH. WE DEVELOP AND MANUFACTURE PRODUCTS WHICH ARE DISTRIBUTED GLOBALLY BY OUR PARTNERS.
Our strategy
In gastroenterology our focus is to improve the safety profile and efficacy of molecules that are already on the market.
In dermatology we aim to develop novel therapies which have minimal side-effects.
In healthtech we are developing cutting-edge intelligent medical devices to assist with clinical decision-making; our first device aids endoscopists in the detection of colonic mucosal lesions.
Our clinical focus
Cosmo is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech.
Products which Cosmo has developed include: Lialda®/ Mezavant®/Mesavancol® and Uceris®/Cortiment®, for the treatment of ulcerative colitis; GI Genius™, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview®, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo® for the treatment of travellers’ diarrhoea (‘TD’) and Winlevi® for the treatment of acne.
Proprietary technology
The Company’s extensive galenic experience, which led to the development of the proprietary multi-matrix technology MMX®, provides an excellent basis for the development of new, patentable, yet lower-risk products, manufactured at the Company’s own current good manufacturing practices (‘cGMP’) approved plant. Cosmo has a demonstrated ability to successfully identify unmet medical needs, manage the drug development process and obtain regulatory approval for new products. Cosmo then licenses its approved products to partners with strong marketing and sales expertise.
Our target therapies
Cosmo’s therapeutic focus is on the oral and endoscopic treatment of colon diseases, primarily bowel diseases and colorectal cancer prevention. Our MMX® technology allows the delivery of active pharmaceutical ingredients into the lumen of the colon through tablets, in a delayed and controlled way, with the effect that the active pharmaceutical ingredients can be applied to the full length of the colon.
Approved products in the market
Lialda®/Mezavant®/Mesavancol® is once-daily mesalamine tablet approved to help get active, mild to moderate Ulcerative Colitis into remission.
UCERIS®/Cortiment® is an oral tablet formulation which delivers budesonide directly to the lumen of the colon.
Winlevi® (Clascoterone cream 1%) is a prescription medicine used on the skin (topical) to treat acne vulgaris in people 12 years of age and older.
GI Genius™ is a computer-aided polyp detection system that uses artificial intelligence to detect colorectal polyps. GI Genius™ is approved in Europe, Australia, United Arab Emirates, and Israel and is available through our partner Medtronic.
Lumeblue® (Methylene Blue MMX®) is approved in the EU for the visualization
of colorectal lesions during colonoscopy.
Aemcolo®/Relafalk® is the first GI antibiotic with MMX® technology and is approved in the U.S. (Aemcolo®) and in Europe (Relafalk®) for the treatment of Travellers’ Diarrhoea (TD). The application of MMX® technology to Rifamycin SV MMX® allows the antibiotic to be delivered directly into the colon, avoiding unwanted systemic side effects.
Eleview® is a medical device approved in U.S., EU, Canada, and Japan, which enables the safer and faster removal of colonic lesions.
Products in clinical development
Breezula® (Clascoterone solution) is a novel androgen receptor inhibitor that targets androgen receptors in the scalp and is currently being studied for the treatment of androgenetic alopecia (‘AGA’).
Methylene Blue MMX® is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy.
Rifamycin SV MMX® – IBS-D is a new formulation to treat colonic infections and IBS-D. The application of MMX® technology to Rifamycin SV MMX® allows the antibiotic to be delivered directly into the colon, avoiding unwanted systemic side effects.
CB-03-10 (Cortexolone 17α-valerate-21-propionate) is a highly potent oral androgen receptor (AR) and Glucocorticoid Receptors (GR) antagonist for the treatment of solid tumors.
CB-01-33 (Colesevelam) is a bile acid sequestrant approved in the USA in May 2000 for the reduction of elevated LDL cholesterol in patients with primary hypercholesterolemia. The product is currently in the formulation development phase for the treatment of bile acid diarrhea (BAD).
GI Genius™ Cosmo is actively developing a new pipeline of Artificial Intelligence applications in endoscopy, to solve unmet clinical needs across the GI space, toward a more effective standard of care.